189 related articles for article (PubMed ID: 37688780)
1. Targeted Polymersome Delivery of a Stapled Peptide for Drugging the Tumor Protein p53:BCL-2-Family Axis in Diffuse Large B-Cell Lymphoma.
Schnorenberg MR; Hawley KM; Thomas-Toth AT; Watkins EA; Tian Y; Ting JM; Leak LB; Kucera IM; Raczy MM; Kung AL; Hubbell JA; Tirrell MV; LaBelle JL
ACS Nano; 2023 Dec; 17(23):23374-23390. PubMed ID: 37688780
[TBL] [Abstract][Full Text] [Related]
2. A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma.
Luo Q; Pan W; Zhou S; Wang G; Yi H; Zhang L; Yan X; Yuan L; Liu Z; Wang J; Chen H; Qiu M; Yang D; Sun J
Oncol Res; 2020 Sep; 28(4):331-344. PubMed ID: 32093809
[TBL] [Abstract][Full Text] [Related]
3. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
[TBL] [Abstract][Full Text] [Related]
4. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
[TBL] [Abstract][Full Text] [Related]
5. Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.
Klanova M; Andera L; Brazina J; Svadlenka J; Benesova S; Soukup J; Prukova D; Vejmelkova D; Jaksa R; Helman K; Vockova P; Lateckova L; Molinsky J; Maswabi BC; Alam M; Kodet R; Pytlik R; Trneny M; Klener P
Clin Cancer Res; 2016 Mar; 22(5):1138-49. PubMed ID: 26467384
[TBL] [Abstract][Full Text] [Related]
6. HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression.
Luo C; Yu T; Young KH; Yu L
J Zhejiang Univ Sci B; 2022 Aug; 23(8):666-681. PubMed ID: 35953760
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
8. The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity.
Thompson RC; Vardinogiannis I; Gilmore TD
PLoS One; 2013; 8(5):e62822. PubMed ID: 23667527
[TBL] [Abstract][Full Text] [Related]
9. Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2.
Mahadevan D; Morales C; Cooke LS; Manziello A; Mount DW; Persky DO; Fisher RI; Miller TP; Qi W
PLoS One; 2014; 9(6):e95184. PubMed ID: 24893165
[TBL] [Abstract][Full Text] [Related]
10. BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFNγ-STAT1-IRF1-p53 axis in diffuse large B-cell lymphoma.
Camicia R; Bachmann SB; Winkler HC; Beer M; Tinguely M; Haralambieva E; Hassa PO
J Cell Sci; 2013 May; 126(Pt 9):1969-80. PubMed ID: 23487038
[TBL] [Abstract][Full Text] [Related]
11. Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
Deng M; Xu-Monette ZY; Pham LV; Wang X; Tzankov A; Fang X; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Hagemeister F; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Liu P; Young KH
Mol Cancer Res; 2021 Feb; 19(2):249-260. PubMed ID: 33154093
[TBL] [Abstract][Full Text] [Related]
12. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.
Li L; Pongtornpipat P; Tiutan T; Kendrick SL; Park S; Persky DO; Rimsza LM; Puvvada SD; Schatz JH
Leukemia; 2015 Aug; 29(8):1702-12. PubMed ID: 25882699
[TBL] [Abstract][Full Text] [Related]
13. BCL-W is dispensable for the sustained survival of select Burkitt lymphoma and diffuse large B-cell lymphoma cell lines.
Diepstraten ST; Chang C; Tai L; Gong JN; Lan P; Dowell AC; Taylor GS; Strasser A; Kelly GL
Blood Adv; 2020 Jan; 4(2):356-366. PubMed ID: 31985804
[TBL] [Abstract][Full Text] [Related]
14. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.
Dey J; Deckwerth TL; Kerwin WS; Casalini JR; Merrell AJ; Grenley MO; Burns C; Ditzler SH; Dixon CP; Beirne E; Gillespie KC; Kleinman EF; Klinghoffer RA
Sci Rep; 2017 Dec; 7(1):18007. PubMed ID: 29269870
[TBL] [Abstract][Full Text] [Related]
15. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.
Dasmahapatra G; Lembersky D; Son MP; Patel H; Peterson D; Attkisson E; Fisher RI; Friedberg JW; Dent P; Grant S
Mol Cancer Ther; 2012 May; 11(5):1122-32. PubMed ID: 22411899
[TBL] [Abstract][Full Text] [Related]
16. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma.
Lee JS; Tang SS; Ortiz V; Vo TT; Fruman DA
Oncotarget; 2015 Nov; 6(34):35202-17. PubMed ID: 26460954
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of Chitinase 3-Like-1 Inhibits Cell Proliferation, Promotes Apoptosis, and Enhances Effect of Anti-Programmed Death Ligand 1 (PD-L1) in Diffuse Large B Cell Lymphoma Cells.
Yang X; Fang D; Li M; Chen J; Cheng Y; Luo J
Med Sci Monit; 2021 Mar; 27():e929431. PubMed ID: 33764958
[TBL] [Abstract][Full Text] [Related]
18. Constitutive IP
Bittremieux M; La Rovere RM; Akl H; Martines C; Welkenhuyzen K; Dubron K; Baes M; Janssens A; Vandenberghe P; Laurenti L; Rietdorf K; Morciano G; Pinton P; Mikoshiba K; Bootman MD; Efremov DG; De Smedt H; Parys JB; Bultynck G
Cell Death Differ; 2019 Mar; 26(3):531-547. PubMed ID: 29899382
[TBL] [Abstract][Full Text] [Related]
19. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
Paoluzzi L; Gonen M; Bhagat G; Furman RR; Gardner JR; Scotto L; Gueorguiev VD; Heaney ML; Manova K; O'Connor OA
Blood; 2008 Oct; 112(7):2906-16. PubMed ID: 18591385
[TBL] [Abstract][Full Text] [Related]
20. Selective Covalent Targeting of Anti-Apoptotic BFL-1 by Cysteine-Reactive Stapled Peptide Inhibitors.
Huhn AJ; Guerra RM; Harvey EP; Bird GH; Walensky LD
Cell Chem Biol; 2016 Sep; 23(9):1123-1134. PubMed ID: 27617850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]